Skip to content

Trial Summary

This is an open-label, two-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.


ACTRN/NCT /ethics:


Scientific title:

A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Sponsor / Cooperative group:

Jiangsu HengRui Medicine Co., Ltd.

Trial & Patient Characteristics

Cancer TypeSolid tumours
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2020-09-03
Anticipated End Date2023-12-01

Participating Hospitals

HospitalSouthern Oncology Clinical Research Unit
Clinical Trial CoordinatorMeggan O'Riley
Phone0491 679 039
Principal InvestigatorDr Amitesh Roy
Recruitment StatusRecruiting